Chizhikova Galina, Khotin Mikhail, Bildyug Natalya
Institute of Cytology, Russian Academy of Sciences, Centre for Cell Technologies, Tikhoretsky Ave. 4, 194064 Saint Petersburg, Russia.
Int J Mol Cell Med. 2024;13(4):337-349. doi: 10.22088/IJMCM.BUMS.13.4.337.
Current models of cardiogenic differentiation include a variety of manipulations and stimulating agents, which interfere with the application of such models for preclinical drug testing. So, the aim of this study was to develop an approach for cardiogenic differentiation with a minimum of manipulations and to assess the influence of the extracellular matrix protein collagen IV on the cardiogenic potential of human mesenchymal stem cells (MSCs). Cardiogenic markers were analyzed by immunofluorescence staining and Western blot analysis. The results showed that collagen IV increased the cardiac marker GATA4 and altered the level of muscle actin isoforms, α-smooth muscle actin and α-cardiac muscle actin, in two different lines of human MSCs. The results indicate that the use of matrices containing collagen IV may increase the cardiogenic potential of human MSCs and may be a promising approach to obtain an model for cardiogenic differentiation suitable for preclinical drug discovery.
目前的心脏发生分化模型包括各种操作和刺激剂,这妨碍了此类模型在临床前药物测试中的应用。因此,本研究的目的是开发一种最少操作的心脏发生分化方法,并评估细胞外基质蛋白IV型胶原对人间充质干细胞(MSCs)心脏发生潜能的影响。通过免疫荧光染色和蛋白质印迹分析对心脏发生标志物进行分析。结果表明,IV型胶原增加了心脏标志物GATA4,并改变了两条不同人间充质干细胞系中肌肉肌动蛋白异构体、α-平滑肌肌动蛋白和α-心肌肌动蛋白的水平。结果表明,使用含IV型胶原的基质可能会增加人间充质干细胞的心脏发生潜能,并且可能是获得适合临床前药物发现的心脏发生分化模型的一种有前景的方法。